Level I Pathways

Cancer care is evolving faster than ever. Emerging drugs and technologies offer new treatment options to oncologists and their patients. Some are promising, others less so. Knowing which ones offer real benefit is critical to optimizing outcomes and managing costs. The focus on drug reimbursement is one important and necessary way of addressing costs. But this approach does little to address the vast treatment variation seen in oncology. The real clinical opportunity is in using the right treatment at the right time. Level I Pathways: The Next Step Level I Pathways from Innovent Oncology are the next step in managing the quality of care for cancer patients. Moving beyond broad label indications and public domain guidelines, Level I Pathways refine the options to those with proven clinical effectiveness and the least possible toxicity. When Level I evidence* points to a superior treatment regimen, in terms of efficacy and safety, that is the treatment that is used. If there is no clear evidence of clinical superiority, then costs are factored into the Pathway. Moving Solid Scientific Evidence into Clinical Practice Cancer care is increasingly complex. Level I Pathways are developed and updated by a multidisciplinary Pathways Task Force, which engages a network of more than 1,000 practicing community oncologists to participate in the development of these guidelines for patient care. The work of the taskforce is an ongoing, exhaustive review of documented clinical evidence from an array of sources including published, peer-reviewed outcomes data * Level I evidence is obtained from meta-analysis of multiple, well-designed, controlled studies or from randomized trials.  Level I Pathways copy